Rhythm Pharmaceuticals Reports Strong Q2 Results, Driven by IMCIVREE
Rhythm Pharmaceuticals sees robust Q2 2024 results with $29.1M revenues due to IMCIVREE's success in treating Bardet-Biedl syndrome.
- Latest
- Trending
Rhythm Pharmaceuticals sees robust Q2 2024 results with $29.1M revenues due to IMCIVREE's success in treating Bardet-Biedl syndrome.
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.